Growth-hormone research · Research peptide

Ipamorelin

Also known as ipamorelin acetate

A synthetic growth-hormone secretagogue studied in early research. It is not an FDA-approved drug.[1]

Published evidenceClinical evidence not established

A clinical benefit and a complete safety picture have not been established for the defined material or use reviewed here.

U.S. status: No FDA-approved product identified
Published context: Body-composition and secretagogue research
Form and route: Research ipamorelin preparations · Intravenous
Main uncertainty: The physical and chemical characterization of nominated substances, subcutaneous safety, long-term endocrine effects, and effectiveness for marketed wellness or body-composition claims are not established.

Reviewed Jul 22, 2026 · U.S.-focused reference profile

Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.

Orientation

What this is

Start with identity and research context. Similar names do not establish equivalent products or evidence.

Published name: Ipamorelin
Type: Research peptide
Primary topic: Growth-hormone and body-composition research
Aliases: ipamorelin acetate

Where it has been studied or used

Published research or product contexts. These are not personal indications.

Body-composition and secretagogue research

Why exact identity matters

Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.

What is known

Evidence, in context

Overall published evidenceNo established clinical evidence for this defined material

A clinical benefit and a complete safety picture have not been established for the defined material or use reviewed here. This is a description, not a rating or recommendation.

Body-composition and secretagogue research

Published human evidence context

Evidence not established

Limited human studies have explored intravenous administration in narrow research settings. FDA found insufficient effectiveness data and no clinical safety data for the proposed subcutaneous route.

Form: Research ipamorelin preparations
Route: Intravenous

Limits and source

The physical and chemical characterization of nominated substances, subcutaneous safety, long-term endocrine effects, and effectiveness for marketed wellness or body-composition claims are not established.

Ipamorelin

What this is

Where it has been studied or used

Evidence, in context

Published human evidence context

Risks and unknowns

Published risk information

What remains uncertain

Forms and routes

Research ipamorelin preparations

U.S. status

Research only

Questions worth discussing

Sources and methodology